The reactive center of Cl-inhibitor, a plasma protease inhibitor that belongs to the serpin superfamily, is located on a peptide loop which is highly susceptible to proteolytic cleavage.
Introduction
Serine proteases are controlled in the plasma milieu by protease inhibitors that belong to the serpin (serine protease inhibitor) superfamily, a recently identified family of structurally related glycoproteins (1, 2) . Serpin deficiency or dysfunction is a key pathogenic factor for the development of several clinical syndromes. For example, emphysema is observed with a deficiency of a I-antitrypsin (3), thrombosis with a deficiency of antithrombin (4) , and angioedema with a deficiency of Cl -inhibitor (5) . The mechanism by which serpins inactivate serine proteases has been extensively studied (1, 2) . Inhibitors react with their target proteolytic enzymes to form stable, inactive and covalent equimolar complexes. During enzyme inactivation, the inhibitor reactive center, which is located on a protein loop exquisitely susceptible to proteolysis, is cleaved between adjacent amino acid residues termed P1 and P1. This process irreversibly modifies the conformation of the serpin molecule, creating sites responsible for the rapid metabolic clearance of enzyme-serpin complexes and for the regulation of serpin biosynthesis (6-1 1). The following observations support the notion that serpins undergo major conformational changes when they are cleaved at or next to their reactive center: (a) complex formation between thrombin and antithrombin reduces the ,B-sheet structure of antithrombin from 6-8 to 1-2% (12) ; (b) Met358 residue of al-antitrypsin (residue P1) is found 67 A apart from Ser359 (residue PI) when the inhibitor is cleaved at PI-PV, whereas the distance between C and N in an intact peptide bond is 1.3 A (6, 13) ; (c) proteolytic cleavage of the exposed loops ofa 1-antitrypsin, antithrombin, or Cl-inhibitor strikingly increases the molecular stability of these proteins (7, 14, 15) ; and (d) Cl-inhibitor that has reacted with plasma kallikrein expresses an epitope that is undetectable on the native serpin molecule ( 16). In the study reported here, we have examined further the consequences for the conformation of Cl-inhibitor of proteolytic cleavage of its exposed loop. We have found that an identical site is created when Cl-inhibitor reacts with its target enzymes kallikrein, Cls, and 1-Factor XIIa or when it is catalytically inactivated by neutrophil elastase. These observations have important implications for the understanding of the mechanism responsible for the recognition of inactive serpin molecules by cellular receptors and for their catabolism.
Methods
Proteins. Cl-inhibitor (17), kallikrein (18), , Cls (20) , neutrophil elastase (21) , and recombinant al-antitrypsin Met358 (22) were prepared using published procedures. High molecular weight protein standards (myosin, ,B-galactosidase, phosphorylase b, BSA, and ovalbumin) were obtained from Bio-Rad Laboratories, Richmond, CA.
Electrophoretic studies. SDS-PAGE was performed using vertical slab gels and a Bio-Rad Protean II system (23). Before electrophoresis, the samples were incubated for 5 min in a boiling water bath. For reduced SDS-PAGE, the samples were boiled in the presence of0.64 M Bl-mercaptoethanol.
Antibodies. MAbs 4C3 and 3C7 were obtained as described earlier (16) . In brief, a BALB/c mouse was immunized with 50 ,sg of the protein mixture that resulted from the inactivation for 60 min at 37°C of 1.5 gM kallikrein by 1.7 ,uM Cl-inhibitor (1.7 ,gM). The 7 .4, containing 10 mM EDTA and 20% normal rabbit serum. Thereafter, the blots were incubated for 2 h with a 1:10,000 dilution of ascites fluids, washed three times, incubated for 3 h with '25I-labeled F(ab')2 fragment of sheep anti-mouse Ig (New England Nuclear), and finally washed four times. All the above described incubation steps were performed at room temperature under rotative agitation. For autoradiography, the blots were exposed 15-48 h at -70'C to Typox-RP-L-Film NIF films (Typon, Burgdorf, Switzerland) using intensifying screens.
Protein stability. Reaction of Cl-inhibitor with its target enzymes. Previous studies have shown that the enzymatic activity of kallikrein, Cls, or 13-Factor XIIa is inhibited by Cl-inhibitor (25, 26) , a reaction that is accompanied by the formation of 1:1 stoichiometric enzyme-inhibitor complexes and of cleaved C 1-inhibitor (16, (27) (28) (29) (30) (31) . To probe the structure of the products of the reaction of Cl-inhibitor with C Is or 13-Factor XIIa, we have employed MAb 4C3, which identifies a neoepitope created on C 1-inhibitor after the inactivation of plasma kallikrein (16) .
By solid-phase RIA, the binding site for 4C3 was expressed by C 1-inhibitor that had reacted with CIs (Fig. 2, circles) or 1-Factor XIIa (Fig. 2, diamonds) . The binding of 4C3 to the protein mixture that resulted from the incubation ofC l -inhibitor with kallikrein is also illustrated (Fig. 2, dotted line) . The various molecular forms of C 1-inhibitor that are detectable immunoblotting, Control experiments with MAb 3C7 indicated that the transfer of the C 1-inhibitor-C Is complex (Mr, 185,000), (3-Factor XIIa-C1-inhibitor complex (Mr, 135,000), native Cl-inhibitor (Mr, 105,000), and modified Cl-inhibitor (Mr, 95,000) onto the nitrocellulose sheets was adequate (Fig.  3, lanes A and C) . Further studies employing 4C3 demonstrated that the neoepitope detected by this antibody was located on the CI-inhibitor-Cls complex (Mr, 190,000; (Fig. 4, lane D) . Moreover, the epitope for MAb 4C3 was not created when heat-inactivated Cl-inhibitor was exposed to catalytically active kallikrein (Table I) . However, once formed, this epitope was not altered by a 1-h incubation at 70'C (Table I) .
Studies with fragments produced by limited proteolysis of Cl-inhibitor by neutrophil elastase. Neutrophil elastase cleaves and inactivates Cl-inhibitor (32) . When the products of the reaction of neutrophil elastase (1.8 pmol) with Cl-inhibitor (140 pmol) were analyzed by SDS-PAGE, two large fragments were observed, with Mr values of 88,000 and 77,000, respectively (Fig. 5, lane C) . These fragments were termed I'" (Me, 88,000) and F (Mr, 77,000). To assess whether these fragments had retained inhibitory activity, the above described protein mixture was incubated with 190 pmol 3-Factor XIIa. This treatment resulted in the disappearance of I' and in the formation of a new component having an Mr of 120,000, which is in reasonable agreement with the sum of the Mr values of I' and (3-Factor XIIa (88,000 + 28,000 = 116,000) (Fig. 5, lane D) . In 1. Abbreviations used in this paper: I' and IF, Cl-inhibitor fragments produced by cleavage of the native inhibitor with neutrophil elastase. contrast, the addition of A-Factor XIIa did not modify the electrophoretic characteristics of I" (Fig. 5, lane D) . The binding of MAb 4C3 to I' and I' was then examined by solid-phase RIA. The site for 4C3 was absent in a protein mixture containing intact Cl-inhibitor and I' (Fig. 6, diamonds) , but it became detectable when I" was present in the system (Fig. 6 , circles).
Discussion
Peptide epitopes include antigenic determinants formed by random coiled sequences of adjacent amino acid residues, as well as determinants created by the assembly of residues that can be located far apart in the primary sequence ofthe antigen (33, 34) . The former are termed sequential or contiguous epitopes, whereas the latter are designated conformational or dis- contiguous epitopes (34) . The site for antibody 4C3 is of sequential nature because it withstands boiling. However, this site is expressed in a much weaker fashion by virgin Cl-inhibitor than by Cl-inhibitor that has reacted with plasma kallikrein (16) . Thus, its emergence demonstrates that the conformation of the native serpin molecule has been modified. In the present study, we have examined the circumstances involved in the genesis of this modification. Our principal conclusion is that the expression ofthe epitope for 4C3 is probably a general consequence of proteolytic cleavage of the exposed loop of Cl-inhibitor at or next to the reactive site peptide bond. This site is created when Cl-inhibitor inactivates its target enzymes (Fig. 2) , a reaction that is accompanied by cleavage of the serpin molecule at its reactive site, PI residue Arg44 (35, 36) . It is also created by the second cleavage of Cl-inhibitor with neutrophil elastase (Fig. 6) . Involvement of Cl-inhibitor reactive center during this cleavage is established by the observation that the resulting species, fragment IF, is an inactive molecule that cannot form a covalent complex with l-Factor XIIa (Fig. 5) . The elastase of Pseudomonas aeruginosa cleaves Cl-inhibitor at the P3 residue Val"12 (35) , and therefore, this residue is probably also the target for neutrophil elastase. Another mechanism could create the site for 4C3.
The stability of aI -antitrypsin or antithrombin is increased by proteolysis of the exposed loop of these serpins (7, 14, 15) ; a parallel observation has been made here with C1-inhibitor.
Hence, the site for 4C3 may become accessible when the native stressed conformation ofC 1-inhibitor is converted into a more stable and relaxed state. However, the experiment with heatdenatured Cl-inhibitor showed that increasing the molecular stability without proteolytic cleavage was not sufficient to expose the site for 4C3 (Table I) .
Serpin-proteolytic enzyme complexes involving antithrombin, a1-antitrypsin, and a2-antiplasmin are rapidly cleared from the blood stream, while this is not the case for the respective native inhibitors (8-10). For example, the fractional metabolic rate of antithrombin-thrombin is 11 times higher Cleavage ofCl-Inhibitor by Serine Proteases 703 than the value determined for native antithrombin (8) . Similar observations have been made comparing the clearance of a2-antiplasmin-plasmin or a2-antiplasmin-trypsin with the clearance of native antiplasmin (10) . In addition, cold antithrombin-thrombin and a 1 -antitrypsin-trypsin compete for the clearance of radioiodinated antithrombin-thrombin (9) . Similarly, the complex between a2-antiplasmin and plasmin (but not antitrypsin-trypsin) competes for the clearance of 1251I-a2-antiplasmin-plasmin (10) . Rapid metabolic clearance is also observed with complexes involving Cl-inhibitor. Increased enzyme-dependent catabolism of this inhibitor is found in patients with hereditary angioedema (37, 38) or rheumatoid arthritis (39) , who have activation of the proteolytic pathways dependent on Cl-inhibitor. These results have led to the suggestion that receptor-mediated pathways are implicated in the clearance of serpin-serine protease complexes (8) (9) (10) . A corollary for this proposition is that bimolecular enzyme-inhibitor complexes should possess a specific recognition site that allows for their cellular binding and uptake. Moreover, for the simplicity and the efficiency of such a clearance system, an identical site should be expressed not only by enzyme-inhibitor complexes, but also by serpin molecules that have been cleaved and inactivated by other mechanisms. The neoepitope identified by 4C3 has characteristics expected from such a site since it is undetectable on native Cl -inhibitor, but is expressed on complexes formed between C 1-inhibitor and its target enzymes, plasma kallikrein, Cl s, or (-Factor XIIa, and cleaved and inactivated by neutrophil elastase on C 1-inhibitor.
